EULAR recommendations for neuropsychiatric systemic lupus erythematosus vs usual care: Results from two European centres

Rheumatology (United Kingdom)

Volumn 54, Issue 7, 2015, Pages 1270-1278

  Pamfil, Cristina ^a   Fanouriakis, Antonis ^b   Damian, Laura ^c   Rinzis, Mirela ^c   Sidiropoulos, Prodromos ^b   Tsivgoulis, Georgios ^d   Rednic, Simona ^a   Bertsias, George ^b,e   Boumpas, Dimitrios T ^b,d,e  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^c Spitalul Clinic Judetean de Urgenta Cluj   (Romania)

^d NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^e INSTITUTE OF MOLECULAR BIOLOGY AND BIOTECHNOLOGY   (Greece)

Author keywords

EULAR recommendations; Immunosuppressive therapy; MRI; Neuropsychiatric SLE

Indexed keywords

ANTIVITAMIN K; AZATHIOPRINE; CYCLOSPORIN A; FIBRINOLYTIC AGENT; METHOTREXATE; RITUXIMAB;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; ASEPTIC MENINGITIS; BRAIN INFARCTION; CARDIOVASCULAR RISK; CEREBROSPINAL FLUID ANALYSIS; CEREBROVASCULAR DISEASE; CLINICAL FEATURE; COGNITIVE DEFECT; CONFUSION; CRANIAL NEUROPATHY; DISEASE ACTIVITY; ELECTROENCEPHALOGRAM; FEMALE; FIBRINOLYTIC THERAPY; HEADACHE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MENTAL DISEASE; MONTREAL COGNITIVE ASSESSMENT; MOOD DISORDER; MYELITIS; NERVE CONDUCTION; NEUROPSYCHIATRIC DISEASE; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PSYCHOSIS; RADICULOPATHY; RECURRENT DISEASE; SEIZURE; SLEDAI; SPINAL CORD DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 84936876543     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu482     Document Type: Article

References (30)

1. Zirkzee EJ, Huizinga TW, Bollen EL et al. Mortality in neuropsychiatric systemic lupus erythematosus (NPSLE). Lupus 2014;23:31-8.
2. Brey RL, Holliday SL, Saklad AR et al. Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology 2002;58:1214-20.
3. Hanly JG, McCurdy G, Fougere L, Douglas JA, Thompson K. Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance. J Rheumatol 2004;31:2156-62.
4. Borowoy AM, Pope JE, Silverman E et al. Neuropsychiatric lupus: the prevalence and autoantibody associations depend on the definition: results from the 1000 faces of lupus cohort. Semin Arthritis Rheum 2012; 42:179-85.
5. Hanly JG, Urowitz MB, Sanchez-Guerrero J et al. Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum 2007;56:265-73.
6. Hanly JG, Urowitz MB, Su L et al. Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2010;69:529-35.
7. Bertsias GK, Boumpas DT. Pathogenesis, diagnosis and management of neuropsychiatric sle manifestations. Nat Rev Rheumatol 2010;6:358-67.
8. Bertsias GK, Ioannidis JP, Aringer M et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 2010;69:2074-82.
9. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40: 1725.
10. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on prognosis studies in SLE. Arthritis Rheum 1992;35:630-40.
11. Gladman D, Ginzler E, Goldsmith C et al. The development and initial validation of the systemic lupus international collaborating clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363-9.
12. Yee CS, Farewell VT, Isenberg DA et al. The use of systemic lupus erythematosus disease activity index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. Rheumatology 2011;50: 982-8.
13. Barr SG, Zonana-Nacach A, Magder LS, Petri M. Patterns of disease activity in systemic lupus erythematosus. Arthritis Rheum 1999;42:2682-8.
14. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999;42:599-608.
15. Nasreddine ZS, Phillips NA, Bedirian V et al. The montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005;53: 695-9.
16. Hanly JG, Urowitz MB, Su L et al. Short-term outcome of neuropsychiatric events in systemic lupus erythematosus upon enrollment into an international inception cohort study. Arthritis Rheum 2008;59:721-9.
17. Luyendijk J, Steens SC, Ouwendijk WJ et al. Neuropsychiatric systemic lupus erythematosus: lessons learned from magnetic resonance imaging. Arthritis Rheum 2011;63:722-32.
18. Toledano P, Sarbu N, Espinosa G, Bargallo N, Cervera R. Neuropsychiatric systemic lupus erythematosus: magnetic resonance imaging findings and correlation with clinical and immunological features. Autoimmun Rev 2013; 12:1166-70.
19. Appenzeller S, Vasconcelos Faria A, Li LM, Costallat LT, Cendes F. Quantitative magnetic resonance imaging analyses and clinical significance of hyperintense white matter lesions in systemic lupus erythematosus patients. Ann Neurol 2008;64:635-43.
20. Castellino G, Padovan M, Bortoluzzi A et al. Single photon emission computed tomography and magnetic resonance imaging evaluation in SLE patients with and without neuropsychiatric involvement. Rheumatology 2008;47: 319-23.
21. Sachdev P, Chen X, Wen W. White matter hyperintensities in mid-adult life. Curr Opin Psychiatry 2008;21:268-74.
22. Jauch EC, Saver JL, Adams HP Jr et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013;44:870-947.
23. El-Magadmi M, Bodill H, Ahmad Y et al. Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women. Circulation 2004;110:399-404.
24. Parker B, Al-Husain A, Pemberton P et al. Suppression of inflammation reduces endothelial microparticles in active systemic lupus erythematosus. Ann Rheum Dis 2014;73: 1144-50.
25. Ainiala H, Hietaharju A, Loukkola J et al. Validity of the new American College of Rheumatology criteria for neuropsychiatric lupus syndromes: a population-based evaluation. Arthritis Rheum 2001;45:419-23.
26. Hanly JG, Cassell K, Fisk JD. Cognitive function in systemic lupus erythematosus: results of a 5-year prospective study. Arthritis Rheum 1997;40:1542-3.
27. Waterloo K, Omdal R, Husby G, Mellgren SI. Neuropsychological function in systemic lupus erythematosus: a five-year longitudinal study. Rheumatology 2002; 41:411-5.
28. Hanly JG, Su L, Omisade A, Farewell VT, Fisk JD. Screening for cognitive impairment in systemic lupus erythematosus. J Rheumatol 2012;39:1371-7.
29. Adhikari T, Piatti A, Luggen M. Cognitive dysfunction in SLE: development of a screening tool. Lupus 2011;20: 1142-6.
30. Rutjes AW, Reitsma JB, Coomarasamy A, Khan KS, Bossuyt PM. Evaluation of diagnostic tests when there is no gold standard. A review of methods. Health Technol Assess 2007;11:iii, ix-51.